Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Electrocore ( (ECOR) ) has shared an update.
On December 17, 2024, electroCore, Inc. announced a definitive agreement to acquire NeuroMetrix, Inc., a healthcare company specializing in neurotechnology devices for chronic pain and diabetes, including its Quell platform. This acquisition will enhance electroCore’s position in the bioelectronic health and wellness sector by expanding its product portfolio with non-invasive therapies. The merger, expected to close by the first quarter of 2025, is anticipated to be accretive to electroCore’s financials, leveraging existing distribution channels to accelerate the adoption of Quell Fibromyalgia solutions. The transaction excludes the DPNCheck technology, which is expected to be divested by NeuroMetrix before the completion of the deal.
More about Electrocore
electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company that focuses on the commercialization of medical devices for the management and treatment of specific medical conditions using non-invasive vagus nerve stimulation technology. They aim to promote general well-being and human performance in the United States and select international markets.
YTD Price Performance: 139.96%
Average Trading Volume: 96,976
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $93.6M
See more data about ECOR stock on TipRanks’ Stock Analysis page.
